Press Releases

Now Available: Veeva Compass Suite of Commercial Data Products

Complete suite of modern patient, prescriber, and national data products for today’s complex therapies

Compass Prescriber includes HCP-level projections for more than 4,000 brands and their prescriptions and procedures

PLEASANTON, CA — Jan. 30, 2024 — Veeva Systems (NYSE: VEEV) today announced the availability of the full Veeva Compass Suite of commercial data products for a more complete view into patient populations and HCP-level insight. Veeva Compass Prescriber and Veeva Compass National are the first to deliver projections for both retail prescriptions and complex procedures, including in-office administered therapies, injections, and infusions. Veeva Compass Suite also includes Compass Patient, granular, longitudinal patient data spanning prescriptions, procedures, and diagnoses. Veeva Compass products are licensed by the brand and give brands unlimited data access, including historical data.

“Veeva Compass Suite delivers the data the industry needs for a faster, more precise approach to commercialization,” said Mike Rifflard, vice president, operations, rare disease, ANI Pharmaceuticals. “With Veeva Compass, we accelerated our product launch by giving field teams a more complete and timely view of our customers.”

Veeva Compass data products are available for the U.S. market today and include:

  • Veeva Compass Patient provides granular, anonymous patient data, including prescriptions, procedures, and diagnoses for market assessment, patient journey analytics, patient finding, HCP segmentation and targeting, and triggers and alerts.
  • Veeva Compass Prescriber includes projected prescriptions and procedures data at the HCP, HCO, and zip code levels for HCP segmentation and targeting, field planning, incentive compensation, and competitive intelligence.
  • Veeva Compass National is projected prescriptions and procedures data at the state and national levels for forecasting, market share tracking, and commercial strategy.

“The availability of the full Veeva Compass Suite of data products is a major milestone for the industry and for Veeva,” said Peter Stark, executive vice president and general manager, Veeva Compass. “We are excited to deliver significant innovations in commercial data for life sciences. Powered by a simple, modern data architecture, Veeva Compass handles both retail and complex therapies for more than 4,000 brands.”

Additional Information
For more on Veeva Compass, visit:
Connect with Veeva on LinkedIn:

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at


Alison Borris
Veeva Systems

Interested in learning more about how Veeva can help?